AF
MGX icon

Allworth Financial’s Metagenomi Therapeutics MGX Stock Holding History

Allworth Financial’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$595 Hold
500
– – ﹤0.01% 4815
2026
Q1 		$670 Hold
500
– – ﹤0.01% 4670
2025
Q4 		$810 Buy
+500
New +$1.08K ﹤0.01% 4418

Other funds holding MGX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Allworth Financial's MGX Position: Q2 2026 in Review

Allworth Financial held its Metagenomi Therapeutics (MGX) position steady in Q2 2026 at 500 shares worth $595. The position accounts for ﹤0.01% of the portfolio, ranked #4815.

Allworth Financial first reported a position in MGX in Q4 2025 and has held it in 3 quarters since. The position peaked at $810 in Q4 2025. 43 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

  • Allworth Financial held 500 shares of Metagenomi Therapeutics worth $595 as of Q2 2026.
  • Allworth Financial left its Metagenomi Therapeutics share count unchanged in Q2 2026.
  • Metagenomi Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #4815 holding.
  • Allworth Financial first reported a position in Metagenomi Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Allworth Financial's Metagenomi Therapeutics position peaked at $810 in Q4 2025.
  • 43 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.